{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-166208","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2022-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.611225+00:00","generated_at":"2026-06-25T05:05:12.991478+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Forte Biosciences shareholders elect two Class II directors, ratify auditor, approve equity plan","bullets":["Steven Kornfeld elected Class II director with 3,366,874 votes for; Patricia Walker with 3,335,739 for, 1,612,841 withheld; 3,373,670 broker non-votes.","Ratification of Mayer Hoffman McCann as independent auditor for FY2022: 8,107,698 for, 157,062 against, 57,490 abstentions.","Increase to 2021 Equity Incentive Plan approved: 2,826,803 for, 2,106,190 against, 15,587 abstentions, 3,373,670 broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-166208","json":"https://secwatch.observer/filing/0001193125-22-166208.json","markdown":"https://secwatch.observer/filing/0001193125-22-166208.md","text":"https://secwatch.observer/filing/0001193125-22-166208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522166208/0001193125-22-166208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522166208/d348649d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:05:12.991478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}